| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
BioVie Inc (NASDAQ: BIVI)
BIVI Technical Analysis
5
| As on 9th Jun 2023 BIVI STOCK Price closed @ 5.79 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 3.25 & Strong Buy for SHORT-TERM with Stoploss of 3.84 we also expect STOCK to react on Following IMPORTANT LEVELS. |
BIVISTOCK Price
| Open | 5.72 | Change | Price | % |
| High | 5.89 | 1 Day | 0.12 | 2.12 |
| Low | 5.46 | 1 Week | -0.05 | -0.86 |
| Close | 5.79 | 1 Month | -1.72 | -22.90 |
| Volume | 224800 | 1 Year | 0.19 | 3.39 |
| 52 Week High 13.38 | 52 Week Low 1.38 | ||||
NASDAQ USA Most Active Stocks
| TSLA | 244.40 | 4.06% |
| TTOO | 0.07 | -12.50% |
| SOFI | 8.18 | 0.74% |
| FFIE | 0.33 | 6.45% |
| PONO | 1.72 | 2.38% |
| AMD | 124.92 | 3.20% |
| IDEX | 0.06 | 0.00% |
| NKLA | 0.70 | 14.75% |
| AMZN | 123.43 | -0.66% |
| AAPL | 180.96 | 0.22% |
NASDAQ USA Top Gainers Stocks
NASDAQ USA Top Losers Stocks
| BIVI Daily Charts |
BIVI Intraday Charts |
Whats New @ Bazaartrend |
BIVI Free Analysis |
|
|
BIVI Important Levels Intraday
| RESISTANCE | 6.62 |
| RESISTANCE | 6.35 |
| RESISTANCE | 6.19 |
| RESISTANCE | 6.02 |
| SUPPORT | 5.56 |
| SUPPORT | 5.39 |
| SUPPORT | 5.23 |
| SUPPORT | 4.96 |
BIVI Forecast May 2024
| 4th UP Forecast | 11.26 |
| 3rd UP Forecast | 9.51 |
| 2nd UP Forecast | 8.42 |
| 1st UP Forecast | 7.34 |
| 1st DOWN Forecast | 4.24 |
| 2nd DOWN Forecast | 3.16 |
| 3rd DOWN Forecast | 2.07 |
| 4th DOWN Forecast | 0.32 |
BIVI Weekly Forecast
| 4th UP Forecast | 7.31 |
| 3rd UP Forecast | 6.82 |
| 2nd UP Forecast | 6.52 |
| 1st UP Forecast | 6.22 |
| 1st DOWN Forecast | 5.36 |
| 2nd DOWN Forecast | 5.06 |
| 3rd DOWN Forecast | 4.76 |
| 4th DOWN Forecast | 4.27 |
BIVI Forecast2024
| 4th UP Forecast | 30.96 |
| 3rd UP Forecast | 22.89 |
| 2nd UP Forecast | 17.9 |
| 1st UP Forecast | 12.91 |
| 1st DOWN Forecast | -1.33 |
| 2nd DOWN Forecast | -6.32 |
| 3rd DOWN Forecast | -11.31 |
| 4th DOWN Forecast | -19.38 |
BioVie Inc ( NASDAQ USA Symbol : BIVI )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
BIVI Business Profile
BioVie Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of drugs therapies in the United States. Its products in pipeline include BIV201, which completed Phase IIa clinical trial for the treatment of ascites due to chronic liver cirrhosis; and NE3107, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease and Phase I clinical trial for the treatment of Parkinson's disease. The company is also developing NE3107, which is in pre-clinical stage for the treatment of multiple myeloma and prostate cancer. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is based in Santa Monica, California. Address: 2120 Colorado Avenue, Santa Monica, CA, United States, 90404
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service